TLX2 and cardiovascular disorder: These foundations now support the rational design of isoform-selective NCX modulators that could lead to targeted therapies for a variety of neurodegenerative and cardiovascular diseases, realizing the long-anticipated clinical potential of NCX as a druggable target.